Decoding 6 Analyst Evaluations For Viridian Therapeutics
Decoding 6 Analyst Evaluations For Viridian Therapeutics
解读Viridian Therapeutics的6位分析师评估
A clear picture of Viridian Therapeutics's...Ratings for Viridian Therapeutics (NASDAQ:VRDN) were provided by 6 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
在过去的三个月中，有6位分析师为Viridian Therapeutics（纳斯达克: VRDN）进行了评级，显示了一些看好和看淡的观点。
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
下表提供了他们最近的评级快照，展示了情绪在过去30天中的演变情况，并将其与之前的月份进行比较。
Insights from analysts' 12-month price targets are revealed, presenting an average target of $29.5, a high estimate of $42.00, and a low estimate of $23.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 6.05%.
分析师在12个月的价格目标中提供了见解，呈现出平均目标为29.5美元，高估值为42.00美元，低估值为23.00美元。由于分析师将平均价格目标减少了6.05％，因此情绪发生了负向转变。
Understanding Analyst Ratings: A Comprehensive Breakdown
分析师评级：全面解析
A clear picture of Viridian Therapeutics's...
通过对最近分析...
登录免费看全文
登录/注册
资讯热榜
更新时间